Virtu Financial’s Innate Pharma IPHA Stock Holding History

Virtu Financial’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,740	Closed	-$54K	–	1742
2021 Q4	$54K	Sell	11,740 -97,832	-89%	-$521K	0.01%	1323
2021 Q3	$676K	Buy	+109,572	New	+$472K	0.06%	340

Other funds holding IPHA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Virtu Financial's IPHA Position: Q1 2022 in Review

Virtu Financial sold out of Innate Pharma (IPHA) in Q1 2022, closing a stake of 11,740 shares — an estimated $54K sold.

Virtu Financial first reported a position in IPHA in Q3 2021 and held it in 2 quarters. The position peaked at $676K in Q3 2021. 13 funds tracked by Wall St. Rank hold IPHA as of Q1 2022.

Virtu Financial reported no remaining Innate Pharma position as of Q1 2022 after selling out during the quarter.
Virtu Financial sold 11,740 Innate Pharma shares in Q1 2022, an estimated $54K.
Virtu Financial first reported a position in Innate Pharma in Q3 2021 and held it in 2 quarters.
Virtu Financial's Innate Pharma position peaked at $676K in Q3 2021.
13 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2022.

Based on Virtu Financial's 13F filing for Q1 2022, filed 17 May 2022.